nach oben

Current Heart Failure Reports

Erschienen in:

14.02.2019 | Emergency Medicine (F Peacock, Section Editor)

Vasodilator Therapies in the Treatment of Acute Heart Failure

verfasst von: Daniel B. Holt Jr, Peter S. Pang

Erschienen in: Current Heart Failure Reports | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Vasodilators are commonly recommended to treat acute heart failure (AHF), yet they are infrequently used. This review aims to evaluate the clinical utility of traditional, historical, and novel vasodilators in the treatment of AHF.

Recent Findings

No traditional vasodilator (i.e., nitroglycerin) therapy definitely improves short- or long-term outcomes. Despite repeated efforts to develop new pharmacologic treatments, no novel therapy outperforms traditional management. At the present time, we continue to recommend traditional vasodilators, such as nitroglycerin.

Summary

The use of select vasodilators in the treatment of AHF improves hemodynamics and provides short-term relief; however, data regarding long-term benefits is lacking.

Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. American Heart Association Council on epidemiology and prevention statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–e492. https://doi.org/10.1161/CIR.0000000000000558.CrossRefPubMed

Heidenreich PA, Albert NM, Allen LA, American Heart Association Advocacy Coordinating Committee, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Radiology and Intervention, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606–19. https://doi.org/10.1161/HHF.0b013e318291329a.CrossRefPubMedPubMedCentral

Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the atherosclerosis risk in communities study). Am J Cardiol. 2008;101(7):1016–22. https://doi.org/10.1016/j.amjcard.2007.11.061.CrossRefPubMed

Storrow AB, Jenkins CA, Self WH, Alexander PT, Barrett TW, Han JH, et al. The burden of acute heart failure on U.S. emergency departments. JACC Heart Fail. 2014;2(3):269–77. https://doi.org/10.1016/j.jchf.2014.01.006.CrossRefPubMedPubMedCentral

Wong YW, Fonarow GC, Mi X, Peacock WF IV, Mills RM, Curtis LH, et al. Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: findings from the acute decompensated heart failure registry emergency module (ADHERE-EM). Am Heart J. 2013;166(2):349–56. https://doi.org/10.1016/j.ahj.2013.05.014.CrossRefPubMed

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey de Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):e147–239. https://doi.org/10.1016/j.jacc.2013.05.019.CrossRefPubMed

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. https://doi.org/10.1093/eurheartj/ehw128.CrossRefPubMed

Acute Heart Failure Syndromes. Critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. American College of Emergency Medicine, May, 2007. https://www.acep.org/patient-care/clinical-policies/acute-heart-failure-syndromes/#sm.00000ixjak0swgfqwwnufn8dak1b0.

Alexander P, Alkhawam L, Curry J, Levy P, Pang PS, Storrow AB, et al. Lack of evidence for intravenous vasodilators in ED patients with acute heart failure: a systematic review. Am J Emerg Med. 2015;33(2):133–41. https://doi.org/10.1016/j.ajem.2014.09.009.CrossRefPubMed

10.

Collins SP, Storrow AB. Acute heart failure. In: Tintinalli JE, Stapczynski JS, Ma OJ, et al., editors. Tintinalli’s emergency medicine: a comprehensive study guide. New York: McGraw-Hill Education; 2016.

11.

Fonarow GC. The treatment targets in acute decompensated heart failure. Rev Cardiovasc Med. 2001;2(Suppl 2):S7–S12.PubMed

12.

Wakai A, McCabe A, Kidney R, Brooks SC, Seupaul RA, Diercks DB, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev. 2013;8:CD005151. https://doi.org/10.1002/14651858.CD005151.pub2.CrossRef

13.

Nelson GI, Silke B, Ahuja RC, Hussain M, Taylor SH. Haemodynamic advantages of isosorbide dinitrate over frusemide in acute heart-failure following myocardial infarction. Lancet. 1983;1(8327):730–3.CrossRefPubMed

14.

Verma SP, Silke B, Hussain M, Nelson GIC, Reynolds GW, Richmond A, et al. First-line treatment of left ventricular failure complicating acute myocardial infarction: a randomised evaluation of immediate effects of diuretic, venodilator, arteriodilator, and positive inotropic drugs on left ventricular function. J Cardiovasc Pharmacol. 1987;10(1):38–46.CrossRefPubMed

15.

Beltrame JF, Zeitz CJ, Unger SA, Brennan RJ, Hunt A, Moran JL, et al. Nitrate therapy is an alternative to furosemide/morphine therapy in the management of acute cardiogenic pulmonary edema. J Card Fail. 1998;4(4):271–9.CrossRefPubMed

16.

Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287(12):1531–40 Erratum in: JAMA 2002 Aug 7;288(5):577.

17.

Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351(9100):389–93.CrossRefPubMed

18.

Levy P, Compton S, Welch R, Delgado G, Jennett A, Penugonda N, et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med. 2007;50(2):144–52.CrossRefPubMed

19.

Mullens W, Abrahams Z, Francis GS, Skouri HN, Starling RC, Young JB, et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol. 2008;52(3):200–7. https://doi.org/10.1016/j.jacc.2008.02.083.CrossRefPubMed

20.

Silvers SM, Howell JM, Kosowsky JM, Rokos IC, Jagoda AS, American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. Ann Emerg Med. 2007;49(5):627–69.CrossRefPubMed

21.

Long B, Koyfman A, Gottlieb M. Management of heart failure in the emergency department setting: an evidence-based review of the literature. J Emerg Med. 2018. https://doi.org/10.1016/j.jemermed.2018.08.002.

22.

CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429–35.CrossRef

23.

SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.CrossRef

24.

Annane D, Bellissant E, Pussard E, Asmar R, Lacombe F, Lanata E, et al. Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema. Circulation. 1996;94(6):1316–24.CrossRefPubMed

25.

O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32–43. https://doi.org/10.1056/NEJMoa1100171.CrossRefPubMed

26.

Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293(15):1900–5.CrossRefPubMed

27.

Peacock WF, Chandra A, Char D, Collins S, der Sahakian G, Ding L, et al. Clevidipine in acute heart failure: results of the a study of blood pressure control in acute heart failure-a pilot study (PRONTO). Am Heart J. 2014;167(4):529–36. https://doi.org/10.1016/j.ahj.2013.12.023.CrossRefPubMed

28.

• Pang PS, Butler J, Collins SP, et al. Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). Eur Heart J. 2017;38(30):2364–73. https://doi.org/10.1093/eurheartj/ehx196. This randomized controlled trial investigated the safety and efficacy of an angiotensin II type I receptor ligand, for use in the treatment of acute heart failure.CrossRefPubMedPubMedCentral

29.

Felker GM, Butler J, Collins SP, Cotter G, Davison BA, Ezekowitz JA, et al. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (biased ligand of the angiotensin receptor study in acute heart failure). JACC Heart Fail. 2015;3(3):193–201. https://doi.org/10.1016/j.jchf.2014.09.008.CrossRefPubMed

30.

• Packer M, O'Connor C, McMurray JJV, et al. TRUE-AHF Investigators. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017;376(20):1956–64. https://doi.org/10.1056/NEJMoa1601895. This randomized controlled trial investigated ularitide, an analogue of the natural vasodilator urodilantin, in the treatment of acute heart failure.CrossRefPubMed

31.

Mitrovic V, Lüss H, Nitsche K, et al. Effects of the renal natriuretic peptide uro- dilatin (ularitide) in patients with decom- pensated chronic heart failure: a double- blind, placebo-controlled, ascending-dose trial. Am Heart J. 2005;150:1239.CrossRefPubMed

32.

Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J. 2006;27:2823–32.

33.

• Teerlink JR, Cotter G, Davison BA, et al. RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381(9860):29–39. https://doi.org/10.1016/S0140-6736(12)61855-8. This randomized controlled trial investigated the effects of serelaxin, a recombinant of human relaxin-2, responsible for hemodynamic changes in pregnancy, in the treatment of acute heart failure.CrossRefPubMed

34.

Conrad KP. Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol. 2011;301(2):R267–75. https://doi.org/10.1152/ajpregu.00156.2011.CrossRefPubMedPubMedCentral

35.

Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep. 2010;7(2):75–82. https://doi.org/10.1007/s11897-010-0010-z.CrossRefPubMedPubMedCentral

36.

Ponikowski P, Metra M, Teerlink JR, et al. Design of the RELAXin in acute heart failure study. Am Heart J. 2012;163(2):149–55.e1. https://doi.org/10.1016/j.ahj.2011.10.009.CrossRefPubMed

37.

RELAXin in acute heart failure-2 - RELAX-AHF-2. American College of Cardiology, May 8, 2017. https://www.acc.org/latest-in-cardiology/clinical-trials/2017/05/07/16/09/relax-ahf-2.

38.

Collins SP, Pang PS, Lindsell CJ, Kyriacou DN, Storrow AB, Hollander JE, et al. International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. Eur J Heart Fail. 2010;12(11):1253–60. https://doi.org/10.1093/eurjhf/hfq133.CrossRefPubMedPubMedCentral

39.

Novartis heart drug portfolio hit by failed serelaxin study. Reuters, March 22, 2017 http://www.reuters.com/article/ us-novartis-heart-idUSKBN16T0QG.

Titel: Vasodilator Therapies in the Treatment of Acute Heart Failure
verfasst von: Daniel B. Holt Jr
Peter S. Pang
Publikationsdatum: 14.02.2019
Verlag: Springer US
Erschienen in: Current Heart Failure Reports / Ausgabe 1/2019
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-019-0421-4

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypotonie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Vasodilator Therapies in the Treatment of Acute Heart Failure

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

His Bundle Pacing in Heart Failure—Concept and Current Data

Implementation of Heart Transplantation Program to Advanced Heart Failure Patients in Brazil

Cardiac Contractility Modulation and Baroreflex Activation Therapy in Heart Failure Patients

The Role of Troponin for Acute Heart Failure

Early Treatment in Emergency Department Patients with Acute Heart Failure: Does Time Matter?

Quality Measures in Heart Failure: the Past, the Present, and the Future

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie